| Followers | 111 |
| Posts | 9096 |
| Boards Moderated | 0 |
| Alias Born | 04/19/2010 |
Wednesday, April 06, 2022 10:30:25 AM
There is zero chance that SHMN is getting 7.5 million in 3 years from Brainwise. ZERO.
Look at how that PR is worded. First it's all estimated.
Then they are partnered with J Industries in Ghana. So SOHM is "manufacturing" the product here at some mystery place. They don't have a manufacturing facility on their filings. So one has to assume they are having stuff manufactured elsewhere. They claim to be purchasing a manufacturing facility, but with what? The 6000 dollars in cash they have? So whatever money they get for Brainwise will have to split between the manufacturing site and J Industries in Ghana for marketing it.
And why would they manufacture something in the US and ship it to Ghana in the first place. Freight costs are at an all time high with oil prices. Ghana is a pharmaceutical manufacturing hot spot. Labor prices are way lower than the US. Why not just manufacture the fish oil supplement there?
So much about SHMN doesn't add up....
Look at how that PR is worded. First it's all estimated.
Then they are partnered with J Industries in Ghana. So SOHM is "manufacturing" the product here at some mystery place. They don't have a manufacturing facility on their filings. So one has to assume they are having stuff manufactured elsewhere. They claim to be purchasing a manufacturing facility, but with what? The 6000 dollars in cash they have? So whatever money they get for Brainwise will have to split between the manufacturing site and J Industries in Ghana for marketing it.
And why would they manufacture something in the US and ship it to Ghana in the first place. Freight costs are at an all time high with oil prices. Ghana is a pharmaceutical manufacturing hot spot. Labor prices are way lower than the US. Why not just manufacture the fish oil supplement there?
So much about SHMN doesn't add up....
Recent SHMN News
- SOHM Inc. Releases White Paper on ABBIE, a Cas9-Guided Integrase Enabling Stable Gene Integration and Creation of SKOV3-GYS1 Cell Line for Drug Discovery • ACCESS Newswire • 11/06/2025 02:30:00 PM
- SOHM Notes FDA's Evolving Gene-Editing Framework in Context of Ongoing ABBIE Platform Development • ACCESS Newswire • 11/04/2025 02:30:00 PM
